GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CEL-SCI Corp (AMEX:CVM) » Definitions » Debt-to-EBITDA

CVM (CEL-SCI) Debt-to-EBITDA : -0.53 (As of Jun. 2024)


View and export this data going back to 1991. Start your Free Trial

What is CEL-SCI Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

CEL-SCI's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $2.17 Mil. CEL-SCI's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $9.96 Mil. CEL-SCI's annualized EBITDA for the quarter that ended in Jun. 2024 was $-22.73 Mil. CEL-SCI's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 was -0.53.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for CEL-SCI's Debt-to-EBITDA or its related term are showing as below:

CVM' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.83   Med: -0.5   Max: -0.05
Current: -0.51

During the past 13 years, the highest Debt-to-EBITDA Ratio of CEL-SCI was -0.05. The lowest was -0.83. And the median was -0.50.

CVM's Debt-to-EBITDA is ranked worse than
100% of 270 companies
in the Biotechnology industry
Industry Median: 1.41 vs CVM: -0.51

CEL-SCI Debt-to-EBITDA Historical Data

The historical data trend for CEL-SCI's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CEL-SCI Debt-to-EBITDA Chart

CEL-SCI Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.69 -0.52 -0.48 -0.48 -0.49

CEL-SCI Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.49 -0.53 -0.60 -0.52 -0.53

Competitive Comparison of CEL-SCI's Debt-to-EBITDA

For the Biotechnology subindustry, CEL-SCI's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CEL-SCI's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CEL-SCI's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where CEL-SCI's Debt-to-EBITDA falls into.



CEL-SCI Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

CEL-SCI's Debt-to-EBITDA for the fiscal year that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.969 + 11.603) / -27.561
=-0.49

CEL-SCI's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.168 + 9.964) / -22.728
=-0.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2024) EBITDA data.


CEL-SCI  (AMEX:CVM) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


CEL-SCI Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of CEL-SCI's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


CEL-SCI Business Description

Traded in Other Exchanges
Address
8229 Boone Boulevard, Suite 802, Vienna, VA, USA, 22182
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company's core capabilities that include are drug discovery, research, development and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
Executives
Geert R Kersten director, officer: Chief Executive Officer 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Patricia B Prichep officer: Sr. Vice President, Operations 8229 BOONE BLVD., SUITE 802, VIENNA VA 22182
Robert Eugene Watson director 245 N. HIGHLAND AVE NE, SUITE 230-296, ATLANTA GA 30307
Gail K Naughton director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Peter R Young director 8229 BOONE BLVD, STE 802, VIENNA VA 22182
John Cipriano officer: Senior Vice President 8229 BOONE BLVD, SUITE 802, VIENNA VA 22182
Bruno Jean-marie Baillavoine director 8229 BOONE BLVD., SUITE 802, VIENNA VA 22182
Eyal Talor officer: Chief Scientific Officer 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Daniel H Zimmerman officer: Sr. Vice President, Research 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Clara Maximilian De director, officer: President
C Richard Kinsolving director 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Alexander G Esterhazy director 8229 BOONE BLVD, STE 802, VIENNA VA 22182